Innovent Biologics (HKG:1801) granted Roche exclusive global rights to develop, manufacture, and sell IBI3009, a DLL3-targeted antibody-drug conjugate (ADC) candidate.
This collaboration aims to bring treatment options to patients with advanced small-cell lung cancer (SCLC), according to a Thursday filing with the Hong Kong Exchange.
Under the deal, Innovent and Roche will partner on the early-stage development of this ADC candidate, after which Roche will take over full development.
Innovent will receive $80 million in upfront payments and be eligible for up to $1 billion in milestone payments, along with tiered royalties on net sales, the filing stated.
IBI3009 targets DLL3, an antigen significantly overexpressed in certain cancers, particularly SCLC and other neuroendocrine tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.